Susceptibility for NSAIDs-induced apoptosis correlates to p53 gene status in gastric cancer cells

Cancer Investigation

Volumn 26, Issue 9, 2008, Pages 868-877

  Zhang, Yan Jie ^a,b   Dai, Qiang ^a   Wu, Shu Ming ^b   Zhu, Hong Yin ^b   Shen, Guan Feng ^b   Li, En Ling ^b   Xiao, Shu Dong ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Apoptosis; Bax; Heterodimer; NSAIDs; p53

Indexed keywords

ACETYLSALICYLIC ACID; HETERODIMER; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER SUSCEPTIBILITY; DOWN REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SYNTHESIS REGULATION; STOMACH CARCINOMA; UPREGULATION; WILD TYPE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; ASPIRIN; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; DIMERIZATION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; HUMANS; INDOMETHACIN; MUTATION; PROTO-ONCOGENE PROTEINS C-BCL-2; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 57049122911     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900801944872     Document Type: Article

References (31)

1. Bardia, A.; Ebbert, J.O.; Vierkant, R.A.; Limburg, P.J.; Anderson, K.; Wang, A.H.; Olson, J.E.; Vachon, C.M.; Cerhan, J.R. Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality. J Natl Cancer Inst 2007, 99, 881-889.
2. Flossmann, E.; Rothwell, P.M.; British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007, 369, 1603-1613.
3. Rostom, A.; Dubé, C.; Lewin, G.; Tsertsvadze, A.; Barrowman, N.; Code, C.; Sampson, M.; Moher D; U.S. Preventive Services Task Force. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007, 146(5), 376-389.
4. Dai, Y.; Wang, W.H. Non-steroidal anti-inflammatory drugs in prevention of gastric cancer. World J Gastroenterol 2006, 12(18), 2884-2889.
5. Cha, Y.I.; DuBois, R.N. NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med 2007, 58, 239-252.
6. Fecker, L.F.; Stockfleth, E.; Nindl, I.; Ulrich, C.; Forschner, T.; Eberle J.The role of apoptosis in therapy and prophylaxis of epithelial tumours by nonsteroidal anti-inflammatory drugs (NSAIDs). Br J Dermatol 2007, 156 Suppl 3, 25-33.
7. Karl, T.; Seibert, N.; Stöhr, M.; Osswald, H.; Rösl, F.; Finzer, P. Sulindac induces specific degradation of the HPV oncoprotein E7 and causes growth arrest and apoptosis in cervical carcinoma cells. Cancer Lett 2007, 245(1-2), 103-111.
8. Zhou, X.M.; Wong, B.C.; Fan, X.M.; Zhang, H.B.; Lin, M.C.; Kung, H.F.; Fan, D.M.; Lam, S.K. Non-steroidal anti-inflammatory drugs induce apoptosis in gastric cancer cells through up-regulation of bax and bak. Carcinogenesis 2001, 22(9), 1393-1397.
9. Sinicrope, F.A.; Penington, R.C. Sulindac sulfide-induced apoptosis is enhanced by a small-molecule Bcl-2 inhibitor and by TRAIL in human colon cancer cells overexpressing Bcl-2. Mol Cancer Ther 2005, 4(10), 1475-1483.
10. Jeong, S.Y.; Gaume, B.; Lee, Y.J.; Hsu, Y.T.; Ryu, S.W.; Yoon, S.H.; Youle, R.J. Bcl-x(L) sequesters its C-terminal membrane anchor in soluble, cytosolic homodimers. EMBO J 2004, 23(10), 2146-2155.
11. Moriishi, K.; Koura, M.; Matsuura, Y. Induction of Bad-mediated apoptosis by Sindbis virus infection: involvement of pro-survival members of the Bcl-2 family. Virology 2002, 292(2), 258-271.
12. O'Neill, J.W.; Manion, M.K.; Maguire, B.; Hockenbery, D.M. BCL-XL dimerization by three-dimensional domain swapping. J Mol Biol 2006, 356(2), 367-381.
13. Hattori, T.; Ookawa, N.; Fujita, R.; Fukuchi, K. Heterodimerization of Bcl-2 and Bcl-Xl with Bax and Bad in colorectal cancer [J]. Acta Oncologica 2000, 39(4), 495-500.
14. Zhang, Z.; Lapolla, S.M.; Annis, M.G.; Truscott, M.; Roberts, G.J.; Miao, Y.; Shao, Y.; Tan, C.; Peng, J.; Johnson, A.E.; Zhang, X.C.; Andrews, D.W.; Lin, J. Bcl-2 homodimerization involves two distinct binding surfaces, a topographic arrangement that provides an effective mechanism for Bcl-2 to capture activated bax. J Biol Chem 2004, 279(42), 43920-43928.
15. Er, E.; Oliver, L.; Cartron, P.F.; Juin, P.; Manon, S.; Vallette, F.M. Mitochondria as the target of the pro-apoptotic protein Bax. Biochim Biophys Acta 2006, 1757, 1301-1311.
16. Rodriguez-Nieto, S.; Zhivotovsky, B. Role of alterations in the apoptotic machinery in sensitivity of cancer cells to treatment. Curr Pharm Des 2006, 12(34), 4411-4425.
17. Lopez-Beltran, A.; Maclennan, G.T.; de la Haba-Rodriguez, J.; Montironi, R.; Cheng L.Research advances in apoptosis-mediated cancer therapy: a review. Anal Quant Cytol Histol 2007, 29(2), 71-78.
18. Kastan, M.B. Wild-type p53: tumors can't stand it. Cell 2007, 128, 837-840.
19. Selivanova, G.; Wiman, K.G. Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 2007, 26, 2243-2254.
20. de Moraes, E.; Dar, N.A.; de Moura Gallo, C.V.; Hainaut, P. Cross-talks between cyclooxygenase-2 and tumor suppressor protein p53: Balancing life and death during inflammatory stress and carcinogenesis. Int J Cancer 2007, 121, 929-937.
21. Narayanan, B.A. Chemopreventive agents alters global gene expression pattern: predicting their mode of action and targets. Curr Cancer Drug Targets 2006, 6, 711-727.
22. Adams, J.M.; Cory, S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007, 26, 1324-1337.
23. Reed, J.C. Proapoptotic multidomain Bcl-2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities. Cell Death Differ 2006, 13, 1378-1386.
24. Girard-Egrot, A.; Chauvet, J.P.; Gillet, G.; Moradi-Améli, M. Specific interaction of the antiapoptotic protein Nr-13 with phospholipid monolayers is prevented by the BH3 domain of Bax. J Mol Biol 2004, 335(1), 321-331.
25. Shangary, S.; Johnson, D.E. Peptides derived from BH3 domains of Bcl-2 family members: a comparative analysis of inhibition of Bcl-2, Bcl-x(L) and Bax oligomerization, induction of cytochrome c release, and activation of cell death. Biochem 2002, 41(30), 9485-9495.
26. Brajusković, G.; Orolicki, S.V.; Cerović, S.; Usaj, S.K.; Marjanović, S.; Romac, S. Bcl-2 and Bax protein interaction in B-lymphocytes of peripheral blood in patients with chronic lymphocytic leukemia. Vojnosanit Pregl 2005, 62(5), 357-363.
27. Pérez-Navarro, E.; Gavaldà, N.; Gratacòs, E.; Alberch, J. Brain-derived neurotrophic factor prevents changes in Bcl-2 family members and caspase-3 activation induced by excitotoxicity in the striatum. J Neurochem 2005, 92(3), 678-691.
28. Filippovich, I.V.; Sorokina, N.I.; Lisbona, A.; Chérel, M.; Chatal, J.F. Radiation-induced apoptosis in human myeloma cell line increases BCL-2/BAX dimer formation and does not result in BAX/BAX homodimerization. Int J Cancer 2001, 92(5), 651-660.
29. Rodriguez-Feo, J.A.; Fortes, J.; Aceituno, E.; Farre, J.; Ayala, R.; Castilla, C.; Rico, L.; Gonzalez-Fernandez, F.; Garcia-Duran, M.; Casado, S.; Lopez-Farre, A. Doxazosin modifies Bcl-2 and Bax protein expression in the left ventricle of spontaneously hypertensive rats. J Hypertens 2000, 18, 307-315.
30. Salah-Eldin, A.E.; Inoue, S.; Tsukamoto, S.; Aoi, H.; Tsuda, M. An association of Bcl-2 phosphorylation and Bax localization with their functions after hyperthermia and paclitaxel treatment. Int J Cancer 2003, 103(1), 53-60.
31. Rudner, J.; Jendrossek, V.; Belka, C. New insights in the role of Bcl-2/Bcl-2 and the endoplasmic reticulum. Apoptosis 2002, 7(5), 441-447.